Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unraveling MARCH6's role in cancer progression and metabolism from protein homeostasis to oncogenesis.

Pharmacological research·2026

Same author

Bioorthogonal Iridium(III) Complexes: A New Frontier of Luminescent Iridium(III) Complexes for Biomedical Applications.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Same author

Dual-Receptor Targeted Imaging of Cancer Cells with a Bioorthogonal Iridium(III)-Based Probe.

Inorganic chemistry·2026

Same author

Dissecting Mitochondrial Sulfur Dioxide Generation Mechanism in Rheumatoid Arthritis with a NIR Luminogenic Iridium(III)-Based Probe.

Analytical chemistry·2026

Same author

Imaging mitochondrial hydrogen sulfide in multicellular spheroids using a near-infrared iridium(III) complex.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026

Same author

Facilitating Quantitation of Mitochondrial G-Quadruplex DNA with an Iridium(III) Two-Photon Phosphorescence Lifetime Imaging Probe.

Journal of the American Chemical Society·2025

Search research articles

Related Experiment Video

Updated: Dec 14, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Interfering with S100B-effector protein interactions for cancer therapy.

Ke-Jia Wu¹, Wanhe Wang², Hui-Min David Wang³

¹State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa 999078, Macao SAR, China.

Drug Discovery Today

|July 18, 2020

Summary

S100 calcium-binding protein B (S100B) drives cancer growth. This review explores virtual screening to find new drugs targeting S100B interactions, offering novel therapeutic strategies for malignant tumors.

More Related Videos

Mapping Dysfunctional Protein-Protein Interactions in Disease

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Experiment Videos

Last Updated: Dec 14, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Mapping Dysfunctional Protein-Protein Interactions in Disease

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Area of Science:

Biochemistry and Molecular Biology
Oncology
Drug Discovery

Background:

S100 calcium-binding protein B (S100B) is frequently overexpressed in malignant tumors.
S100B influences cancer cell proliferation and metabolism through molecular interactions.
Targeting S100B-effector protein interactions presents a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

To review the discovery of S100B-effector protein interaction inhibitors using virtual screening (VS).
To identify and discuss novel S100B-effector protein targets for in silico drug discovery.
To highlight the potential of targeting alternative S100B interactions beyond the S100B-p53 pathway.

Main Methods:

Literature review of virtual screening studies focused on S100B inhibitors.
Analysis of known S100B-effector protein interactions relevant to cancer.
In silico approaches for identifying and validating new drug targets.

Main Results:

Virtual screening has identified some S100B inhibitors, primarily targeting the S100B-p53 interaction.
There is a significant unmet need and opportunity for discovering modulators of other S100B-effector protein interactions.
Several S100B-effector protein interactions are potential targets for computational drug discovery.

Conclusions:

Developing inhibitors for diverse S100B-effector protein interactions is crucial for advancing cancer therapy.
Virtual screening and in silico analysis are valuable tools for discovering novel S100B-targeted cancer drugs.
Exploring new S100B targets beyond p53 can lead to more effective treatments for various malignant tumors.